DrugPatentWatch Database Preview
Pertuzumab - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for pertuzumab
| Tradenames: | 1 |
| Patents: | 199 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for pertuzumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for pertuzumab |
Recent Clinical Trials for pertuzumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Rochester | Phase 2 |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Fundacion Clinic per a la Recerca Biomédica | Phase 2 |
Recent Litigation for pertuzumab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
| Genentech, Inc. v. Amgen Inc. | 2018-06-21 |
| Genentech, Inc. v. Celltrion, Inc. | 2018-01-12 |
Pharmacology for pertuzumab
| Mechanism of Action | HER2/Neu/cerbB2 Antagonists |
Patent Text Search: US Patents for pertuzumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Celgene Corporation (Summit, NJ) | 2039-02-26 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2025-01-21 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2025-05-20 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Hoffmann-La Roche Inc. (Nutley, NJ) | 2025-08-12 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for pertuzumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 3042659 | Start Trial |
| Canada | 2688694 | Start Trial |
| Portugal | 2164514 | Start Trial |
| Canada | 2858012 | Start Trial |
| Canada | 2722109 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for pertuzumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015 00006 | Denmark | Start Trial | PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805 |
| 00717 | Netherlands | Start Trial | PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| 642 | Luxembourg | Start Trial | PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805 |
| 0717 | Netherlands | Start Trial | PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| 2015 | Austria | Start Trial | PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
